Melphalan: all 415 studies that test it

Page 2 of 5. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Cord Blood Transplantation for Patients With CancerTerminatedNCT01359254Phase 2Results posted
• Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsTerminatedNCT01350258Phase 1/2Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results posted
• Intra-arterial Chemotherapy for the Treatment of Intraocular RetinoblastomaTerminatedNCT01293539Phase 2Results posted
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTCompletedNCT01242267Phase 1/2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's DiseaseCompletedNCT01200329Phase 2Results posted
• Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With IsotretinoinCompletedNCT01175356Phase 1Results posted
• Autologous Transplant in HIV Patients (BMT CTN 0803)CompletedNCT01141712Phase 2Results posted
• Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte InfusionsCompletedNCT01131169Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisCompletedNCT01083316Phase 2Results posted
• Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
• Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 StudyActive, not recruitingNCT01054196Phase 1/2Results posted
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure StatesCompletedNCT00997386Phase 2Results posted
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted
• Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic MalignanciesCompletedNCT00943592Phase 1/2Results posted
• High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell TumorsCompletedNCT00936936Phase 2Results posted
• PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous TransplantationCompletedNCT00925782Phase 2Results posted
• Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple MyelomaCompletedNCT00916058Phase 1/2Results posted
• A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL AmyloidosisCompletedNCT00890552Not applicableResults posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaTerminatedNCT00843310Phase 2Results posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Double Cord Blood Transplant for Patients With Malignant and Non-malignant DisordersTerminatedNCT00801931Phase 1/2Results posted
• Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyTerminatedNCT00793650Phase 1/2Results posted
• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
• Low Dose Melphalan and Bortezomib for AML and High-Risk MDSCompletedNCT00789256Not applicableResults posted
• Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2Results posted
• Bortezomib With Melphalan and Prednisone for Multiple MyelomaCompletedNCT00734149Phase 2Results posted
• Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00695409Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• HD Melphalan and SCT in Patients With IGDD or LCDDTerminatedNCT00681044Phase 2Results posted
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
• Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma PatientsCompletedNCT00661544Phase 1/2Results posted
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom BurdenCompletedNCT00651937Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell HistiocytosisTerminatedNCT00618540Phase 2Results posted
• Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer PatientsTerminatedNCT00583622Phase 2Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanCompletedNCT00577278Phase 2Results posted
• Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin LymphomaCompletedNCT00574496Phase 2Results posted
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
• AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & DisordersCompletedNCT00547196Not applicableResults posted
• Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological MalignanciesActive, not recruitingNCT00544466Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk NeuroblastomaTerminatedNCT00539500Phase 2/3Results posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition DiseaseCompletedNCT00520767Phase 2Results posted
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneCompletedNCT00507416Phase 3Results posted
• Allogeneic Transplantation in Patients With Cutaneous T-Cell LymphomaCompletedNCT00506129Phase 2Results posted
• FM 140 vs FM100 Study in Patients With Multiple MyelomaCompletedNCT00505895Phase 2Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast CancerCompletedNCT00429572Phase 2Results posted
• Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT00429026Phase 2Results posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• Cellular Therapy With Cord Blood CellsCompletedNCT00427557Phase 2Results posted
• Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseCompletedNCT00423514Phase 1/2Results posted
• Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaCompletedNCT00357565Phase 2Results posted
• Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's TumorsCompletedNCT00357396Phase 2Results posted
• High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple MyelomaCompletedNCT00349778Phase 2Results posted
• Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.CompletedNCT00325416Phase 1/2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's LymphomaCompletedNCT00265889Phase 2Results posted
• N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk NeuroblastomaCompletedNCT00253435Phase 2Results posted
• Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's LymphomaCompletedNCT00238433Phase 2Results posted
• S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's LymphomaCompletedNCT00233987Phase 2Results posted
• Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple MyelomaCompletedNCT00217438Phase 3Results posted
• Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple MyelomaCompletedNCT00185614Phase 2Results posted
• Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast CancerCompletedNCT00182793Phase 2Results posted
• Autologous Transplant for Multiple MyelomaCompletedNCT00177047Phase 2/3Results posted
• Stem Cell Transplant for Immunologic or Histiocytic DisordersCompletedNCT00176865Phase 2Results posted
• Stem Cell Transplantation for Hematological MalignanciesTerminatedNCT00176839Phase 2/3Results posted
• S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed LymphomaTerminatedNCT00121186Phase 2Results posted
• Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
• 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) AmyloidosisTerminatedNCT00075608Phase 2Results posted
• Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast CancerTerminatedNCT00074269Phase 2Results posted
• Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
• S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisCompletedNCT00064337Phase 2Results posted
• Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00054353Phase 1/2Results posted
• Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric SarcomasCompletedNCT00043979Phase 2Results posted
• S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00040937Phase 2Results posted
• Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesCompletedNCT00038857Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple MyelomaCompletedNCT00006244Phase 2Results posted
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/2Results posted
• Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaCompletedNCT00004088Phase 2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's LymphomaCompletedNCT00003631Phase 2Results posted
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerCompletedNCT00003199Phase 2Results posted
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With SarcomaCompletedNCT00002601Phase 2Results posted
• Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCompletedNCT06425276Phase 4

← Melphalan overview